Fecal immunochemical testing may reduce colorectal cancer mortality
the ONA take:
Population-based fecal immunochemical testing screening for colorectal cancer demonstrated a significant reduction in colorectal cancer mortality despite a short follow-up time, a new study published online in the journal Cancer has shown.
For the prospective cohort study, over 1.1 million Taiwanese people between the ages of 50 and 69 years underwent fecal immunochemical testing screening between 2004 and 2009. Researchers then compared colorectal cancer-specific mortality for a screened group with an unscreened group.
Results showed that fecal immunochemical testing screening reduced colorectal cancer-specific mortality by 62% with a maximum follow-up of 6 years. After adjustments for a self-selection bias, researchers found that screening reduced cancer-specific morality by 10%.
Although the findings show a significant reduction, this study has had a short follow-up time. Researchers plan to continue following-up this large cohort to assess the long-term effect of fecal immunochemical testing screening.
Fecal immunochemical testing screening for colorectal cancer demonstrated a significant reduction in mortality.
Sign Up for Free e-newsletters
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Reflexology, Aromatherapy May Reduce Pain, Anxiety of Brachytherapy for Cervical Cancer
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Mitomycin Extravasation Protocol
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|